Quick-starting of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition

Not Applicable

Recruiting

• Conditions: Ultrasound Finding: Ovulation Inhibition, Ovarian Activities; Cervical Mucus; Serum Hormonal Profile

• Registration Number: NCT06396221
• Lead Sponsor: Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-4-25
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

Inclusion Criteria:<br><br> 1. Women aged 18 - 45 years old<br><br> 2. Body mass index 18-30 kg/m²<br><br> 3. Menstrual interval within 24 - 38 days<br><br> 4. Absence of history of estrogen or progestin allergy and Absence of these compatibles<br> with U.S. medical eligibility criteria category 3 - 4<br><br> 5. Consent to use condom as contraception or have been sterilized<br><br>Exclusion Criteria:<br><br> 1. History of estrogen, progestin or testosterone use within 3 months<br><br> 2. Current pregnant or within 3 months of breastfeeding<br><br> 3. Having ovarian cyst(s) or tumor(s)<br><br> 4. Being a cervical cancer patient or having precancerous cervical lesion

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of ovulation inhibition and classify ovarian activities using transvaginal ultrasound

Secondary Outcome Measures

Name	Time	Method
Level of serum hormonal profiles: Estradiol, Progesterone, LH;Cervical mucus